An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

The UK NHS is set to review around 4,500 more breast cancer cases dating back to 2015 after a review found delayed diagnoses and 20 cases involving unnecessary breast removal surgery.

Hundreds of patients suffered harm under County Durham and Darlington NHS Foundation Trust in north-east England., according to the review.

The Trust has apologized and is using specialists from other hospitals to determine whether more women underwent unnecessary operations or received poor care.

"The trust will complete the reviews already under way covering care between January 2023 and February 2025. It will then look back one year at a time, starting with patients treated in 2022 and working backwards towards 2015," it said in a statement.

Review Could Cover 4,500 Cases

Also read: Alcohol-Linked Cancer Deaths Doubled In US: Colorectal Leads In Men, Breast Leads In Women

Board chair Alison Marshall apologized to women and families affected by the failings.

"I would like to offer a sincere apology to all the women and their families who have been affected by the failings in our breast services," she said, according to the BBC.

"I can't imagine the impact that has had."

She said the Trust could "not turn back the clock" but would be "open, honest and transparent" about the failings.

Chief nurse Gill Hunt said concerns were first raised in 2015 following a "service reconfiguration" and the loss of breast surgical trainee posts.

Till September 2, 2026, a total of 539 cases had been reviewed, and is expected to examine around 4,500 cases if it extends back to 2015.

The Trust said each year's findings will be "carefully considered" before it moves to the next earlier year. As per the report, the review could take five years, with women treated in 2015 potentially having their cases reviewed as late as 2031.

The admission came after the BBC reported last year that more than 200 patients were found to have suffered harm at the CDDFT.

"We have heard again today about the profound and lasting impact that failings in our breast services have had on women and their families," said Chief executive Steve Russell.

"We remain deeply sorry for the harm and distress caused, and for the times when, as a Trust, we should have listened more carefully, asked more questions and acted sooner," Russell added.

About 640 patients have contacted a special helpline seeking a review of their cases. The current review cost about £523,000 in its first year and involved nine reviewers examining around 80 cases a month.

20 Women Had Unnecessary Mastectomies

Read More: FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses

About 514 cases reviewed by the trust so far, between January 2023 and February 2025, alongside the cases of 640 former patients who contacted a dedicated helpline.

Of the 514 cases, 315 patients have been found to have suffered harm, including 77 who were significantly harmed. One patient is known to have died.

The Trust was found to have a high number of mastectomies compared with other NHS trusts, with operations carried out "too quickly".

Breast Cancer Burden In UK

Breast cancer is the most common cancer in the UK, accounting for roughly 15% of all new cancer cases.

Around 60,763 new cases are diagnosed each year, according to Breast Cancer UK. An estimated 14,000-15,000 mastectomies are performed annually in the UK.

What Is A Mastectomy?

A mastectomy is surgery to remove the whole breast. Depending on the cancer, nearby lymph nodes and surrounding tissue may also be removed. It may be performed on one or both breasts depending on the type of cancer and individual risk factors.

Some patients may undergo breast reconstruction after a mastectomy to restore breast shape and symmetry.

The Food Safety and Standards Authority of India (FSSAI) has proposed restricting the manufacture and sale of analogue dairy products as “paneer.”

The draft Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026, seeks to amend the 2011 regulations to specifically include “paneer made of constituents not derived from milk” among products whose sale would be restricted.

The move aims to prevent consumers from being misled about the nature and composition of such products and comes amid concerns over spurious dairy products.

What Does The Proposed Rule Say?

The proposed amendment seeks to insert a new clause under Regulation 2.1.1 of the existing regulations covering “paneer made of constituents not derived from milk.”

Products made using paneer or cheese analogues would therefore have to be clearly identified to consumers.

“Products already licensed or registered under the ‘Analogue in Dairy Context’ category would be required to discontinue the use of the term ‘Paneer’ in their nomenclature, labelling or marketing,” FSSAI said.

“The proposed amendment is aimed at ensuring that the nomenclature and presentation of food products accurately reflect their nature and composition, thereby enabling consumers to make informed choices,” the food regulator added.

Also read: Indian President Urges Celebrities to Stop Endorsing Health-Harming Products: Why It Matters

Since this is a draft regulation, FSSAI has invited objections and suggestions from stakeholders and members of the public.

The draft will be considered after 60 days, and the submissions received during this period will be considered before the proposed amendment is finalised.

Who Will Be Affected?

The proposed amendment would affect food business operators, including hotels, restaurants and catering services, that use substitutes for traditional dairy-based paneer or cheese products.

FSSAI said businesses using such products would need to prominently disclose this information at consumer touchpoints, including menu cards and packaging labels, in accordance with the Food Safety and Standards (Labelling and Display) Regulations.

In August, Maharashtra and Chhattisgarh banned the manufacture and sale of non-dairy paneer, commonly referred to as analogue paneer or analogue cottage cheese.

Dairy Paneer Vs Analogue Paneer

Traditional paneer is a fresh, soft, non-melting cheese commonly used in Indian cuisine. It is made by curdling milk with acidic ingredients such as lemon juice, vinegar or citric acid, followed by separation of the curds from the whey. The curds are then drained and pressed to remove excess water.

Analogue paneer, on the other hand, is made using non-dairy ingredients such as vegetable fats or oils and starches instead of milk fat.

Under FSSAI regulations:

• Paneer must be made from milk.
• Products containing non-dairy ingredients cannot be presented as conventional paneer.
• Analogue products must be appropriately identified so consumers are aware of their nature and composition.

Read More: FSSAI Tightens Food Warning Labels: Even One High Fat, Salt Or Sugar Ingredient Could Trigger A Red Warning

How Can Consumers Check The Product?

Consumers can start by checking the product label and menu description.

• Read the label: Look for terms such as “analogue” or “imitation” where applicable.
• Check the ingredients: Look for non-dairy fats, vegetable oils, starches or other substitutes.
• Check the product description: At restaurants and other food-service establishments, consumers can ask whether the paneer being served is dairy-based or an analogue product.

Home tests sometimes promoted online, including iodine or toor dal tests, should not be treated as definitive methods for identifying adulterated paneer. Laboratory testing is required to establish the composition of a food product reliably.

A blood test that could detect for signs of multiple cancers at the same time could soon becoming a reality in the cancer-screening space.

But while the outcome of the trial is promising, we can’t help but wonder if the blood test could actually replace existing cancer screening tests.

New research published in Nature Medicine show that a multicancer early detection (MCED) test identified cancer signals across 17 cancer types, including ovarian, lung, breast and colorectal cancers.

The prospective PATHFINDER 2 study followed 35,878 adults aged 50 and above.

So, could a single blood test eventually mean fewer mammograms, colonoscopies, or other routine screening tests? The answer to that question is multi-faceted.

How Does A Multicancer Blood Test Work?

Unlike a conventional blood test that measures things such as blood sugar or cholesterol, an MCED test looks for biological signals released by cancer cells into the bloodstream.

It means that one blood sample could potentially look for several cancers at once, including cancers for which there is currently no recommended population screening test.

About The New Study

Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline

In PATHFINDER 2, researchers studied more than 35,000 adults aged 50 and older. The test detected signals across 17 broad cancer types, including cancers of the lung, breast, ovary and colon.

But detecting a cancer signal is not the same as diagnosing cancer.

A positive result has to be followed by diagnostic tests such as imaging, endoscopy or biopsy to determine whether cancer is actually present.

The study also poses a different challenge. If a person receives a negative result, it does not mean they don’t have cancer.

Can It Replace Mammograms Or Colonoscopies?

Also read: Urine & Vaginal Samples May Help Detect Womb Cancer: Lancet Study Suggests Less Invasive Way To Triage Patients

This is something healthcare providers and patients may wonder if MCED test receives a green light.

The manufacturer says the test is intended to complement, not replace, established screening such as mammograms and colonoscopies.

In the large NHS-Galleri randomized trial, adding the blood test to usual care did not reduce the incidence of stage III or IV cancers, the study's primary endpoint.

In performance analyses, sensitivity for all cancers ranged from about 27% to 37% across screening rounds.

That means the test can miss cancers, particularly when they are at an early stage.

Promising But There’s A Catch

The biggest promise of multicancer testing is that it could identify cancers that currently have no routine screening programme, using a relatively simple and non-invasive blood draw.

But the biggest challenge is proving that finding those cancers earlier actually helps people live longer.

A positive result can lead to scans, biopsies and anxiety when cancer is ultimately not found. A negative result could also create false reassurance and risks of delayed treatment.

So does finding cancer this way, early enough and accurately enough, actually change outcomes? That is what will ultimately determine whether multicancer blood tests become a truly valuable screening tool.